Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Farmers Insurance
Moodys
UBS
Johnson and Johnson

Generated: July 16, 2019

DrugPatentWatch Database Preview

Macimorelin acetate - Generic Drug Details

Try a free trialSee Plans and Pricing

« Back to Dashboard

What are the generic sources for macimorelin acetate and what is the scope of macimorelin acetate freedom to operate?

Macimorelin acetate is the generic ingredient in one branded drug marketed by Novo and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Macimorelin acetate has seventy-two patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for macimorelin acetate
International Patents:72
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 2
DailyMed Link:macimorelin acetate at DailyMed
Pharmacology for macimorelin acetate
Synonyms for macimorelin acetate
945212-59-9
AEZS 130
Aib-Trp-gTrp-CHO acetate
AQZ1003RMG
ARD 07 acetate
CHEMBL2364617
D-87575
D-87575 acetate
D-Tryptophanamide, 2-methylalanyl-N-((1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl)-, acetate (1:1)
D10562
DTXSID40241516
EP 1572
EP 1572 acetate
Macimorelin acetate (USAN)
Macimorelin acetate [USAN]
Macrilen
Macrilen (TN)
N2-(2-amino-2-methylpropanoyl-N1-((1R)-1-formamido-2-(1H-indol-3-yl)ethyl)- D-tryptophanamide acetate
SB16910
UNII-AQZ1003RMG

US Patents and Regulatory Information for macimorelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Express Scripts
Harvard Business School
Healthtrust
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.